https://scholars.lib.ntu.edu.tw/handle/123456789/565274
標題: | 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity | 作者: | Lee H.-Y. Lee J.-F. Kumar S. Wu Y.-W. HuangFu W.-C. Lai M.-J. Li Y.-H. Huang H.-L. Kuo F.-C. Hsiao C.-J. Cheng C.-C. CHIA-RON YANG Liou J.-P. |
關鍵字: | 3-Aroylindoles; Anticancer agents; Histone deacetylase inhibitors; Tubulin polymerization inhibition | 公開日期: | 2017 | 卷: | 125 | 起(迄)頁: | 1268-1278 | 來源出版物: | European Journal of Medicinal Chemistry | 摘要: | A series of 3-aroylindole hydroxamic acids (10–17) were developed based on the concept of a structural combination of tubulin and histone deacetylase (HDAC) inhibitors. This was accomplished by introducing hydroxamic acid-containing moieties at the N1 position of the tubulin assembly inhibitor, compound 9 (SCB01A, BPR0L075, phase II trial). Most of synthetic compounds produced in this way displayed comparable HDAC inhibitory activity, and four (10, 12–14) of them also inhibit tubulin assembly. Notably, compound 12 possesses not only tubulin and HDAC inhibitory activity but also shows HDAC6 selectivity over other HDAC isoforms. In addition, it exhibits remarkable inhibitory activity against the growth cancer cells in?vitro and in?vivo (PC3 and RPMI-8226?cells). Notably, it suppresses the growth of multiple myeloma xenografts without leading to the death of teated animals like reference compound. In sum, this study provided potential compounds with safer profiles for cancer treatment. ? 2016 Elsevier Masson SAS |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996524189&doi=10.1016%2fj.ejmech.2016.11.033&partnerID=40&md5=203d00b2da8be27f9915cb5ff53f7b00 https://scholars.lib.ntu.edu.tw/handle/123456789/565274 |
ISSN: | 2235234 | DOI: | 10.1016/j.ejmech.2016.11.033 | SDG/關鍵字: | 3 aroylindole derivative; histone deacetylase inhibitor; hydroxamic acid derivative; indole derivative; n (2 aminophenyl) 4 [6 methoxy 3 (3,4,5 trimethoxybenzoyl)indol 1 ylmethyl]benzamide; n hydroxy 3 [3 [6 methoxy 3 (3,4,5 trimethoxybenzoyl) 1h indol 1 ylsulfonyl]phenyl]acrylamide; n hydroxy 3 [4 [[6 methoxy 3 (3,4,5 trimethoxybenzoyl) 1h indol 1 yl]methyl]phenyl]acrylamide; n hydroxy 4 [ [6 methoxy 3 (3,4,5 trimetoxybenzoyl) 1h indol 1 yl]methyl]benzamide; unclassified drug; antineoplastic agent; HDAC6 protein, human; histone deacetylase; histone deacetylase inhibitor; hydroxamic acid; indole derivative; tubulin; tubulin modulator; animal experiment; animal model; antineoplastic activity; antiproliferative activity; Article; controlled study; drug structure; enzyme inhibition; growth inhibition; human; human cell; in vitro study; in vivo study; male; mouse; nonhuman; protein assembly; structure activity relation; animal; chemistry; drug design; drug effects; HeLa cell line; metabolism; nude mouse; pathology; prostate; Prostatic Neoplasms; tumor cell line; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; HeLa Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Male; Mice, Nude; Prostate; Prostatic Neoplasms; Tubulin; Tubulin Modulators |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。